Flunarizine’s dual action as a calcium channel blocker and SERT inhibitor can make it a multi-target drug candidate for MDD, consistent with new evidence on the involvement of calcium signaling in neuropsychiatric illness. Here, SLC6A4 is linked to major depressive disorder.